Weill Cornell Medical College
Weill Cornell Medical College
New York, New York, United States58 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT07100080 | |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07218380 | |
| A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 1 | 2026-10-07 | NCT02886065 | |
| Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04657081 | |
| Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-10-02 | NCT03478514 | |
| CAR-T Long Term Follow Up (LTFU) Study | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Recruiting | Phase 3 | 2026-10-02 | NCT02445222 | |
| A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period | Hemic and Lymphatic Diseases, Nutritional and Metabolic Diseases, anemia, hematologic disorder, metabolic disease, pyruvate kinase deficiency of red cells | Active, not recruiting | Phase 3 | 2026-09-28 | NCT05144256 | |
| A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-09-28 | NCT05050097 | |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-09-28 | NCT04722146 | |
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 3 | 2026-09-25 | NCT07196748 | |
| A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT07196722 | |
| A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-09-25 | NCT07036523 | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06208150 | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-25 | NCT05552222 | |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT03767244 | |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | CNS demyelinating autoimmune disease, Infections, Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, central nervous system disorder, central nervous system infectious disorder, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, myelitis, neoplasm, nervous system disorder, neurodegenerative disease, optic nerve disorder, optic neuritis, paraneoplastic syndrome, spinal cord disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07100990 | |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-15 | NCT06615479 | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT05520567 | |
| Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver) | HIV | Recruiting | Not applicable | 2026-09-09 | NCT07665372 | |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Active, not recruiting | Phase 3 | 2026-09-09 | NCT03803553 | |
| A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 2 | 2026-08-31 | NCT03505320 | |
| PREcision MEDicine In Achalasia (PREMEDIA) - Cohort | Deglutition Disorders, Digestive System Diseases, achalasia, digestive system disorder, dyskinesia of esophagus, esophageal disorder | Recruiting | Not stated | 2026-08-28 | NCT07293689 | |
| PREcision MEDicine In Achalasia (PREMEDIA) | Deglutition Disorders, Digestive System Diseases, achalasia, digestive system disorder, dyskinesia of esophagus, esophageal disorder | Recruiting | Phase 3 | 2026-08-28 | NCT07293650 | |
| The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study | Embolism and Thrombosis, Leg Ulcer, Skin Ulcer, Skin and Connective Tissue Diseases, Varicose Ulcer, Venous Thrombosis, cardiovascular disorder, skin disorder, thrombotic disease, varicose disease, vascular disorder, vein disorder | Active, not recruiting | Not applicable | 2026-08-27 | NCT05409976 | |
| Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder | Problems Related to Social Environment | Recruiting | Not applicable | 2026-08-12 | NCT05675735 |